<DOC>
	<DOCNO>NCT00101283</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , pemetrexed disodium , gemcitabine , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether give pemetrexed disodium gemcitabine effective give pemetrexed disodium carboplatin treat malignant pleural mesothelioma . PURPOSE : This randomized phase II trial study pemetrexed disodium gemcitabine pemetrexed disodium carboplatin see well combination work compare historical control treat patient advanced malignant pleural mesothelioma .</brief_summary>
	<brief_title>Pemetrexed Plus Gemcitabine Carboplatin Patients With Advanced Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate response rate patient advance malignant mesothelioma pleura treat pemetrexed disodium combine either gemcitabine carboplatin . Secondary - Assess toxic effect regimens patient . - Estimate survival time patient treat regimen . - Correlate smoking status outcome patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . While randomize , study comparative study . Rather , outcomes arm compare historical control rate previous study . Randomization allow simultaneous test two experimental arm . - Arm I : Patients receive intravenous ( IV ) pemetrexed disodium 10 minute carboplatin IV 30 minute day 1 . - Arm II : Patients receive pemetrexed disodium arm I gemcitabine IV 30 minute day 1 8 . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Beginning approximately 5-10 day start chemotherapy continue approximately 3 week completion chemotherapy , patient receive oral folic acid daily cyanocobalamin ( vitamin B12 ) intramuscularly every 9 week . Patients follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 32-60 patient ( 16-30 per treatment arm ) accrue study within 12.8-27.0 month .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm advanced mesothelioma pleura Measurable disease , define RECIST criterion , within 4 week randomization . Patients pleural rind measurable RECIST eligible disease evaluable within 4 week randomization use mesothelioma response criterion May undergone pleurodesis . If pleurodesis perform , must least 2week delay Pemetrexed administration . A CT must perform 2 week pleurodesis serve baseline scan . ECOG Performance Status 0 1 Normal organ marrow function , define : Absolute neutrophil count ≥ 1,500/ul Platelet count ≥ 100,000/ul Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN ( 5 time ULN liver tumor involvement ) Albumin ≥ 2.5 g/dL Creatinine clearance ≥ 45 mL/min Creatinine ≤ 2.0 g/dL Age 18 year Able take folic acid cyanocobalamin ( vitamin B12 ) Willing able take dexamethasone Women childbearing potential sexually active men require use contraception first 3 month study Exclusion Criteria A candidate curative surgery Prior radiation therapy target lesion , unless lesion clearly progress per RECIST criterion prior radiation interval recent radiation therapy enrollment least 4 week Prior systemic chemotherapy mesothelioma . Prior intracavitary cytotoxic drug immunomodulators permit , unless give purpose pleurodesis . Active infection serious concomitant systemic disorder Second primary malignancy , situ malignancy adequately treat basal cell carcinoma skin malignancy treat least 3 year previously evidence recurrence . Treatment investigational agent within 4 week enrollment Known suspect brain metastasis Women must pregnant breastfeed Obviously malnourish weight loss great 10 % precede 6 week Aspirin nonsteroidal antiinflammatory drug 2 day , , 2 day administration pemetrexed disodium ( 5 day , , 2 day administration pemetrexed disodium piroxicam , naproxen , diflunisal , nabumetone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
</DOC>